TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01445587
Drug: Part 1; Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 125mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 125mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the dose will be escalated to 150mg GSK2110183 for the subject enrolled to Cohort 2. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
Study: NCT03932019
Drug: Jitongning tablet(High-dose )
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jitongning tablet,3tablets,bid,treat 12 weeks
Study: NCT03932019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jitongning tablet placebo,3tablets,bid,treat 12 weeks
Study: NCT01445587
Drug: Part 2; Stage 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the completion of PK sampling and the determination of a Recommended Phase 2 Dose (RP2D) of GSK2110183 in Cohorts 1 and 2, subjects will be enrolled into Part 2, Stage 1 of the study. Twenty subjects will be enrolled in Stage 1. If no subject responds, the study will be stopped; otherwise, the study will continue enrollment of Stage 2.
Study: NCT03962634
Drug: Kovanaze Nasal Spray
Normalized name: Kovanaze Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-nasal local anesthetic
Study: NCT04074265
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection containing normal saline will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
Study: NCT02425306
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide, systemic adjuvant
Study: NCT01445587
Drug: Part 2, Stage 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twenty subjects will be enrolled in Part 2, Stage 2. If 4 or fewer of the 40 subjects (Stages 1 and 2) respond, the study will not be deemed as a success for GSK2110183 monotherapy. However, those subjects meeting the criteria for progression (as defined by IMWC Panel 1) who also meet the additional eligibility criteria for salvage therapy may proceed to GSK2110183 + bortezomib salvage therapy. GSK2110183 + bortezomib salvage therapy will be continued until one of the Treatment Discontinuation Criteria is met
Study: NCT00018278
Drug: Nicoderm Patch
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04355247
Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension
Normalized name: methylPREDNISolone 80 mg/mL injectable suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Patients will be admitted to a regular room in the hospital (not ICU)~* They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.~* Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital.
Study: NCT01255163
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SC twice daily
Study: NCT03460041
Drug: Dexmetedomedine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal dexmetedomedine added to bupivacaine for pain management
Study: NCT01261637
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20ml saline
Study: NCT03716115
Drug: N-Acetyl Glucosamine (GInNAC)
Normalized name: N-acetyl-glucosamine thiazoline
DrugBank: N-Acetyl-glucosamine thiazoline (DB03747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-Acetyl glucosamine provided as powder will be reconstituted and administered orally or via NG tube.
Study: NCT02807103
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous 9 pulses : 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.
Study: NCT02807103
Drug: Placebo-cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous 7 pulses : at days 29, 50, 71, 92, 113, 134 and 155.
Study: NCT01028027
Drug: Loteprednol and tobramycin
Normalized name: Loteprednol and tobramycin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loteprednol etabonate and tobramycin ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
Study: NCT04204603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT03758924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid oral solution
Study: NCT02396628
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
Study: NCT02280694
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02280694
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02280694
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02280694
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01831479
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single administration of rosuvastatin 20mg tablet QD for 7 consecutive days
Study: NCT01831479
Drug: Rosuvastatin and olmesartan
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Co-administration of rosuvastatin 20mg tablet and and olmesartan 40mg tablet QD for 7 consecutive days
Study: NCT02880540
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002888
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02381236
Drug: G-202
Normalized name: krill/om-3/dha/epa/phospho/ast 500 mg-86 mg-25 mg-40 mg-202 mg-101 mcg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle for up to 3 cycles
Study: NCT02117258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while placebo will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
Study: NCT03095807
Drug: NNC9204-1706 A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated.
Study: NCT05718466
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02247557
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (N/S) 50ml in single intravesical instillation
Study: NCT03095807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin)
Study: NCT01268163
Drug: European Taxotere®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-100 mg/m\^2 IV
Study: NCT01268163
Drug: American Taxotere®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-100 mg/m\^2 IV
Study: NCT01670370
Drug: R-GemOx
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab Gemcitabine Oxaliplatin
Study: NCT02142140
Drug: Long-acting stimulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.
Study: NCT03037931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline Solution
Study: NCT04370548
Drug: DARE-BV1clindamycin phosphate vaginal gel, 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.
Study: NCT01834547
Drug: caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg
Study: NCT01834547
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00604786
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing is based on IgE level and weight given every 2 or 4 weeks
Study: NCT01621737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle placebo
Study: NCT01516138
Drug: GIK
Normalized name: Surgikos Tip Cleaner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
Study: NCT00910689
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03748537
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After resuscitation, hypoperfusion in the sepsis patients will be treated by fluid resuscitation and vasopressor. Some groups of patients may be not responsive to this treatment (MAP \<65 mmHg), administration of steroids to this group will be blindly randomized (treatment and control group). During resuscitation of septic shock patients with fluid resuscitation and vasopressors, some may not respond to treatment (MAP \< 65 mmHg). Patients who have shock refractory to fluid resuscitation and norepinephrine therapy for more than 0.5 mcg/kg/min will be blindly randomized to receive steroid (treatment group) or placebo (control group). Blood samples will be obtained to determine mitochondrial functioning before, at day 1 and day 7 after administration of study medications in both groups.
Study: NCT01103323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
Study: NCT03791905
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy drug
Study: NCT02306876
Drug: PF-06412562 3mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06412562
Study: NCT02306876
Drug: PF-06412562 15mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06412562
Study: NCT00910689
Drug: Optimal Acute Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: This acute therapy protocol emphasized treatment with a 5-HT1B/D-agonist or triptan. Nonsteroidal anti-inflammatory (NSAID; ibuprofen) and anti-emetic (metoclopramide) medication could be added as needed. The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or anti-emetic were tailored to participant preference, treatment history and acute therapy response. Individualized handouts and a phone call (week 3) of the OAT Run-in were used to help participants evaluate and optimize their acute therapy.
Study: NCT01081353
Drug: Acetylsalicylic Acid (Aspirin BAY1019036)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet of new formula Aspirin under fasting conditions
Study: NCT00551590
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo PO (placebo control for sitagliptin) for three days
Study: NCT00551590
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline IV (placebo control for exendin(9-39)) on two consecutive study days
Study: NCT02900742
Drug: YiQiFang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.
Study: NCT03339700
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 80mg/kg, intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 and -2.
Study: NCT00189488
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02900742
Drug: YangYinFang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.
Study: NCT02900742
Drug: YiQiYangYinFang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.
Study: NCT02900742
Drug: placebo granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
Study: NCT00197587
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: All women received a background of zidovudine from 34 weeks'gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
Study: NCT01614470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral use, administered twice a day (q12h)
Study: NCT00491569
Drug: Sarcosine and D-serine
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00564460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 8 weeks
Study: NCT01034176
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: no dose, tablet, daily, 30 days
Study: NCT04362384
Drug: Prednisolone ointment
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoanal Prednisolone ointment will be prescribed
Study: NCT01703533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strawberry flavored solution and Water for Injection
Study: NCT03217591
Drug: IW-1973
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT03217591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT02555371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be 0.9% sodium chloride solution and will be provided by the study site.
Study: NCT01277237
Drug: lactose tablet
Normalized name: lactose Oral Tablet
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo: lactose tablet 4g/day
Study: NCT01349010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet bid. p.o for 8 weeks
Study: NCT00625248
Drug: Antithrombotics
Normalized name: Enzymes, antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: With or without or discontinuted use of Antithrombotics
Study: NCT03563573
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive a dose of \~8 mg/kg of a placebo capsule
Study: NCT00870454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules twice daily
Study: NCT03863860
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT01555658
Drug: Unfractioned Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents\>33 mm in length in the same coronary vessel, to IV UFH (60 IU/kg intravenous bolus followed by boluses with target activated clotting time 200-250 s)
Study: NCT01241422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 1: participants will receive 2 placebo tablets in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 placebo tablet + 1 placebo capsule in the evening; and on Day 7: 1 placebo tablet in the morning.
Study: NCT02951312
Drug: Glycopyrrolate Inhalation Solution 25mg
Normalized name: glycopyrrolate Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg oral inhalation via eFlow Nebulizer, once daily
Study: NCT02951312
Drug: Glycopyrrolate Inhalation Solution 75mg
Normalized name: glycopyrrolate Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 μg oral inhalation via eFlow Nebulizer, once daily
Study: NCT00798395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily on Day 1-7
Study: NCT02951312
Drug: Glycopyrrolate Inhalation Solution 200mg
Normalized name: glycopyrrolate Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg oral inhalation via eFlow Nebulizer, once daily
Study: NCT02951312
Drug: Glycopyrrolate Inhalation Solution 200mg Jet
Normalized name: glycopyrrolate Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg oral inhalation via inhalation via jet nebulizer, once daily
Study: NCT02951312
Drug: Glycopyrrolate Inhalation Solution 500mg
Normalized name: glycopyrrolate Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg oral inhalation via eFlow nebulizer, once daily
Study: NCT02951312
Drug: Glycopyrrolate Inhalation Solution1000mg
Normalized name: glycopyrrolate Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 μg oral inhalation via eFlow nebulizer, once daily
Study: NCT02951312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0.5 mL oral inhalation via jet nebulizer, once daily
Study: NCT00090129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered subcutaneously three times a week, for 12 weeks in the FT period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment and then again assigned to either placebo or Onercept (150 mg), subcutaneously three times a week, for 16 weeks.
Study: NCT01900197
Drug: 10% Iron Isomaltoside 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered according to local routines and product labeling in doses at the doctors discretion
Study: NCT00423943
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule containing placebo
Study: NCT01313247
Drug: placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills eqv paracetamol are given 2 tablets 4 times daily instead of paracetamol
Study: NCT02699086
Drug: PDC-1421 Capsule
Normalized name: chlorpheniramine maleate / dihydrocodeine bitartrate / phenylephrine hydrochloride Oral Solution [Despec-PDC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
Study: NCT01670955
Drug: Ferrous Sulphate + Folic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
Study: NCT02716818
Drug: Chronocort®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.
Study: NCT02716818
Drug: standard glucocorticoid therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this arm will continue on their standard hydrocortisone therapy
Study: NCT00643799
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg oral capsule once daily for 6 months
Study: NCT01542762
Drug: LMWH
Normalized name: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for the duration of the immobilization (average 6 weeks). If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily).
Study: NCT00073918
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00987246
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical
Study: NCT00987246
Drug: LAS41005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical
Study: NCT01119105
Drug: BC-3781
Approvals — FDA: no, EMA: no, PMDA: no
Description: BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
Study: NCT01119105
Drug: BC-3781
Approvals — FDA: no, EMA: no, PMDA: no
Description: BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
Study: NCT00360555
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT00739583
Drug: CHG 2% w/v and IPA 70% v/v
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin preparation of the surgical site per label of the product. The area for surgery will be prepared for 30 seconds